The fourth quarter in figures
- Net sales were TSEK 5,764 (4,962), +16%.
- The loss after tax was TSEK 20,541 (15,460).
-
The loss per share was
SEK 0.17 (0.23). - The cash flow from current operations was negative in the amount of TSEK 17,352 (14,593).
- The gross margin was 73.5% (61.4%).
- Electrode sales volume increased by 5% and was 12,044 (11,444) units. Repeat sales of electrodes to existing customers increased by 25%.
January - December in figures
- Net sales were TSEK 23,245 (17,890), +30%.
- The loss after tax was TSEK 55,585 (43,174).
-
The loss per share was
SEK 0.51 (0.63). - The cash flow from current operations was negative in the amount of TSEK 51,984 (44,466).
- The gross margin was 69.0% (62.8%).
- Electrode sales volume increased by 24% and was 51,920 (41,712) units. Repeat sales of electrodes to existing customers increased by 31%.
Important events during the quarter
- Overall sales increased by 16% (+10, before currency effects). Sales in
Germany increased by 36% (26% in local currency). Sales in the US skin cancer market increased by 34% while the sales within the skin barrier segment decreased by 46%. SciBase entered into a collaboration agreement with theSkin and Cancer Institute , a leading dermatology network inCalifornia with more than 50 clinics, to pilot Nevisense in several of theirCalifornia locations.
SciBase entered into a collaboration agreement with the Skin and Cancer Reconstructive Surgery Center inCalifornia . This partnership means that an additional dermatology network will help to introduce Nevisense to a broader US market.
- A nominating committee for the Annual General Meeting in 2024 was appointed.
Important events after the end of the period
- No significant events have occurred after the end of the period.
THE GROUP | 2023 | 2022 | 2023 | 2022 |
Net sales, SEK ths | 5 764 | 4 962 | 23 245 | 17 890 |
Gross margin, % | 73,5% | 61,4% | 69,0% | 62,8% |
Equity/Asset ratio, % | 66,9% | 50,6% | 66,9% | 50,6% |
Net indebtness, multiple | 0,49 | 0,98 | 0,49 | 0,98 |
Cash equivalents, SEK ths | 34 121 | 18 832 | 34 121 | 18 832 |
Cashflow from operating activities, SEK ths | -17 352 | -14 593 | -51 984 | -44 466 |
Earnings per share (before and after dilution), SEK | -0,17 | -0,23 | -0,51 | -0,63 |
Shareholder's equity per share, SEK | 0,36 | 0,37 | 0,40 | 0,37 |
Average number of shares, 000' | 119 831 | 68 475 | 107 980 | 68 475 |
Number of shares at closing of period, 000'* | 119 831 | 68 475 | 119 831 | 68 475 |
Share price at end of period, SEK | 0,83 | 3,82 | 0,83 | 3,82 |
Number of sold electrodes, pieces | 12 044 | 11 444 | 51 920 | 41 712 |
Average number of employees | 26 | 21 | 23 | 20 |
This information is information that
This year-end report has not been subject to review by the Company's auditors
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For more information, please contact:
Certified Advisor (CA):
Tel: +46 8 580 065 99
Email: ca@vatorsec.se
About
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at
The company has been on the Nasdaq First North Growth Market exchange since
https://news.cision.com/scibase/r/year-end-report,c3932547
https://mb.cision.com/Main/12371/3932547/2617829.pdf
(c) 2024 Cision. All rights reserved., source